26Unused vials

26 Unused vials

(1) If a vial of a botulinum toxin pharmaceutical benefit from a supply ordered for the treatment of an eligible patient remains unused at the conclusion of the eligible patient’s treatment period, the vial is to be used when the eligible medical practitioner next treats eligible patients under this Special Arrangement. (2) However, subject to subsections (3) and (4), an eligible medical practitioner may hold a small quantity of botulinum toxin pharmaceutical benefits for the treatment of a condition mentioned in Schedule 3, under this Special Arrangement, in an emergency situation. (3) An eligible medical practitioner who is authorised, under this Special Arrangement, to administer a botulinum toxin pharmaceutical benefit that has the listed drug Botulinum Toxin Type A Purified Neurotoxin Complex to treat a treatment condition mentioned in the column in Schedule 3 headed ‘Treatment Condition’ must not hold more than 5 vials of a botulinum toxin pharmaceutical benefit that has the listed drug Botulinum Toxin Type A Purified Neurotoxin Complex. (4) An eligible medical practitioner who is authorised, under this Special Arrangement, to administer a botulinum toxin pharmaceutical benefit that has the listed drug Clostridium Botulinum Type‑A Toxin‑Haemagglutinin Complex to treat a treatment condition numbered 2, 3, 4 or 7 in the column in Schedule 3 headed ‘Treatment Condition Number’ must not hold more than 5 vials of a botulinum toxin pharmaceutical benefit with the Clostridium Botulinum Type A Toxin–Haemagglutinin Complex drug. (5) An eligible medical practitioner who is authorised, under this Special Arrangement, to administer a botulinum toxin pharmaceuctical benefit that has the listed drug IncobotulinumtoxinA to treat a treatment condition numbered 1B, 4A or 7 in the column in Schedule 3 headed ‘Treatment Condition Number’ must not hold more than 5 vials of a botulinum toxin pharmaceutical benefit with the IncobotulinumtoxinA drug. (6) The Chief Executive Medicare must not arrange, or pay for, the replacement of vials of a botulinum toxin pharmaceutical benefit that have expired or have been lost or damaged. (7) An eligible medical practitioner must notify the Chief Executive Medicare by telephone, on the number mentioned in section 28, before transferring vials of a botulinum toxin pharmaceutical benefit that have been supplied under this Special Arrangement to another eligible medical practitioner. (8) A vial of a botulinum toxin pharmaceutical benefit supplied under this Special Arrangement must not be transferred to a medical practitioner who is not an eligible medical practitioner. (9) If an eligible medical practitioner (the first eligible medical practitioner) sends a botulinum toxin pharmaceutical benefit to another registered practice location, or to another eligible medical practitioner, the first eligible medical practitioner is responsible for ensuring that, during transit, the botulinum toxin pharmaceutical benefit is handled and stored in accordance with handling and storage conditions advised by the responsible person. (10) The Chief Executive Medicare must not arrange, or pay, for replacement of any vial of a botulinum toxin pharmaceutical benefit that is lost or damaged during relocation.